◆ TICKERBASE · GLOBAL STOCK FINANCIAL DATA LIBRARY

Kissei Pharmaceutical Co., Ltd. (4547)

Name: Kissei Pharmaceutical Co., Ltd.（4547）— 财务报表历史
Creator: TickerBase
License: https://creativecommons.org/licenses/by/4.0/

来自官方财务报表的收入、利润与现金流历史。

Healthcare · 华尔街（美国） · 最近更新： 2026-10-02

Kissei Pharmaceutical Co., Ltd. researches, develops, manufactures, and sells pharmaceutical products primarily in Japan and internationally. It offers Calogra tablets, for the treatment of ulcerative colitis; Tabneos capsules for the treatment of microscopic polyangiitis and granulomatous polyangiitis; Corsuba Intravenous Dialysis Syringe for the treatment of chronic idiopathic thrombocytopenic purpura; Beova tablets for the treatment of overactive bladder treatment; and Darbepoetin Alfa BS injection JCR for the treatment of renal anemia.

关键数据

市值: JPY 155 billion
收入（截至 2026-03-31 财年）: JPY 97.4B
净利润: JPY 13.8B
毛利率: 47.0%
净利率: 14.1%

查看交互式图表与完整报表 → 估值模型 (DCF) →

年度利润表

利润表	2026-03-31	2025-03-31	2024-03-31	2023-03-31
总收入	JPY 97.4B	JPY 88.3B	JPY 75.6B	JPY 67.5B
毛利	JPY 45.8B	JPY 44.1B	JPY 37.3B	JPY 32.4B
营业利润（EBIT）	(JPY 2.9B)	JPY 5.8B	JPY 4.0B	(JPY 1.1B)
净利	JPY 13.8B	JPY 12.0B	JPY 11.2B	JPY 10.5B

来源：公司公开报告（SEC）。在依赖任何数字前请核对 SEC EDGAR。

资产负债表、现金流、季度数据与完整财务比率见 4547 交互式查看器。 /companies/us/4547

类似公司

4521 · Kaken Pharmaceutical Co., Ltd.

本网站信息仅用于教育与参考，不构成投资建议。不发布目标价或买卖建议。

English version →全部股票

About TickerBase · Data methodology & sources · Privacy · Terms

TickerBase is provided for educational and informational purposes only. It does not constitute financial, investment, tax, or legal advice, or a recommendation to buy, sell, or hold any security. No price targets are published; any per-share value shown in the valuation workbench is generated entirely from reader-supplied assumptions and is not the publisher's view of fair value. Past performance does not predict future results. Figures are approximate and drawn from public filings; one-time items are noted where identified. Do your own research and consult a licensed professional before making any investment decision. The author may or may not hold positions in the securities discussed.